Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration

MLA

Gerrits, Cjh, et al. “Phase I and Pharmacological Study of the New Topoisomerase I Inhibitor GI147211, Using a Daily x 5 Intravenous Administration.” British Journal of Cancer, vol. 73, no. 6, Mar. 1996, pp. 744–50. EBSCOhost, https://doi.org/10.1038/bjc.1996.130.

APA

Gerrits, C., Creemers, G., Schellens, J., Wissel, P., Planting, A., Kunka, R., Selinger, K., de Boer-Dennert, M., Marijnen, Y., Harteveld, M., & Verweij, J. (1996). Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. British Journal of Cancer, 73(6), 744–750. https://doi.org/10.1038/bjc.1996.130

Chicago

Gerrits, Cjh, Gj Creemers, Jhm Schellens, P Wissel, As Planting, R Kunka, K Selinger, et al. 1996. “Phase I and Pharmacological Study of the New Topoisomerase I Inhibitor GI147211, Using a Daily x 5 Intravenous Administration.” British Journal of Cancer 73 (6): 744–50. doi:10.1038/bjc.1996.130.